Please assess the completion status of the following clinical trial:

Trial Title: Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* IBD Group:~  * Biopsy confirmed Crohn's Disease~ * Qualifying scores on Multidimensional Fatigue Inventory and Pittsburgh Sleep Quality Index~* Healthy Volunteer Group:~  * Does not meet any exclusion criteria~Exclusion Criteria:~* IBD Group:~  * Meeting criteria for active alcohol or substance abuse or dependence~ * Current ongoing treatment with Wellbutrin~ * Females who are pregnant or plan to become pregnant within three months~ * Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)~ * Current IBD flare requiring hospitalization with intravenous steroid treatment~ * Other acute medical conditions or a history of chronic inflammatory condition other than IBD~ * Hemoglobin \<10 with age and gender adjustments~ * History of seizure disorder~ * Acute infection within seven days~* Healthy Volunteer Group:~  * History or current episode of psychiatric disorder by Diagnositic and Statistical Manual (DSM-IV)~ * Current ongoing treatment with psychoactive medications~ * Medications for sleep in previous two weeks~ * Females who are pregnant or plan to become pregnant within three months~ * History of IBD, epilepsy, rheumatoid arthritis, lupus~ * Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Behavioral Counseling (Type: OTHER): Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
- Behavioral counseling + bupropion-SR (Type: OTHER): Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
- Healthy Control (Type: NO_INTERVENTION): The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.

Based on this trial design, predict the completion outcome and termination type (if applicable).